YOLFTbeta
ZY

ZYUS Life Sciences Corporation

ZYUS · V · Healthcare / Drug Manufacturers - Specialty & Generic

0.40CAD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.40
Open0.40
Day Range0.40 – 0.40
52-Week Range0.37 – 0.75
Volume0
Market Cap48.31M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.25
Dividend Yield0.00%
Beta0.16
50-Day Avg0.5286
200-Day Avg0.5572

About

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Brent H. Zettl
  • Employees0
  • HeadquartersUnit 204, Saskatoon, SK, Canada, S7N 4L8, Canada
  • Websitehttps://www.zyus.com

Leadership

  • Mr. Brent H. ZettlPresident, CEO, Secretary & Director · b. 1962
  • Mr. John L. KnowlesInterim CFO & Director
  • Dr. Julie Stakiw FRCPC, M.D.Chief Medical Officer
  • Mr. Scott William LivingstoneVice President of Clinical Research
  • Mr. John William-Richard EagleVice President of Finance & Accounting
  • Mr. Tim MillerDirector of Investor Relations & Capital Markets

Financials

Income Statement

Currency: CAD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue207.00K298.00K351.00K481.00K405.00K
Growth (%)-+43.96%+17.79%+37.04%-15.80%
Cost of Revenue64.00K530.00K180.00K352.00K355.00K
Gross Profit143.00K-232.00K171.00K129.00K50.00K
Gross Margin69.08%-77.85%48.72%26.82%12.35%
Operating Expense22.91M16.06M17.36M14.78M14.24M
Operating Income-22.77M-16.30M-17.19M-14.65M-14.19M
Operating Margin-10999.52%-5468.12%-4898.01%-3046.78%-3503.46%
EBITDA--15.43M-42.06M-32.18M-16.60M
EBITDA Margin--5176.85%-11983.19%-6689.60%-4098.52%
Net Income-23.45M-24.66M-42.59M-33.80M-21.73M
Net Income Margin-11330.92%-8274.16%-12134.19%-7028.07%-5365.68%
R&D5.37M2.21M1.31M2.05M2.86M
R&D as % of Total Revenue2593.72%740.94%372.93%425.99%705.93%
Interest Expense2.74M5.24M3.27M755.00K2.41M
Interest Expense % of Total Revenue1324.64%1759.40%932.19%156.96%594.57%

Balance Sheet

Currency: CAD2022-12-312023-12-312024-12-312025-12-31
Total Assets64.71M41.63M14.67M5.08M
Total Liabilities59.97M18.51M20.02M26.20M
Total Equity4.74M23.11M-5.34M-21.12M
Cash212.00K3.98M1.90M233.00K
Net Debt31.49M2.81M7.59M13.56M

Cash Flow

Currency: CAD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-16.86M-9.57M-17.95M-9.88M-9.23M
Financing Cash Flow14.61M9.63M17.14M5.97M7.55M
Capital Expenditure4.99M560.00K281.00K46.00K11.00K
Free Cash Flow-21.85M-10.13M-18.23M-9.92M-9.24M
FCF to OCF129.59%105.85%101.57%100.47%100.12%

Earnings

Report DateAug 28, 2023Nov 28, 2023Dec 31, 2023May 29, 2024Aug 28, 2024Nov 28, 2024Dec 31, 2024Apr 29, 2025Nov 25, 2026
EPS Estimate-0.07-0.08-0.07-0.09-0.08-0.07-0.07-0.07-
EPS Actual-0.28-0.06-0.06-0.05-0.07-0.05-0.05-0.05-
Surprise-300.00%25.00%10.92%44.44%12.50%28.57%31.29%28.57%-
TimingAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap48.31M
Enterprise Value67.92M
Trailing P/E0.00
Forward P/E0.00
Price / Sales129.18
Price / Book4.41
EPS-0.25
Book Value-0.335
Revenue (TTM)374.00K
Gross Profit (TTM)-58.00K
EBITDA-10.09M
Profit Margin0.00%
Operating Margin-2745.68%
Return on Equity-3516.83%
Return on Assets-87.29%
Shares Outstanding80.52M
Shares Float38.97M
Beta0.16
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%